5234KAND567, the first selective small molecule CX3CR1 antagonist in clinical development, mediates anti-inflammatory cardioprotective effects in rodent models of atherosclerosis and myocardial infarction
暂无分享,去创建一个
A. Gabrielsen | I. Spyridopoulos | H. Arthur | J. Pernow | T. Olin | M. Wågberg | R. F. Danielson | S. Abdelmoaty